AVE 8112

Drug Profile

AVE 8112

Alternative Names: AVE 8112A; AVE8112

Latest Information Update: 05 Nov 2015

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis; The Michael J. Fox Foundation for Parkinson's Research
  • Class Antidementias
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 02 Oct 2015 Discontinued - Phase-I for Parkinson's disease (Adjunctive treatment) in USA (PO)
  • 01 Jan 2013 Phase-I clinical trials in Parkinson's disease (adjunctive treatment) in USA (PO)
  • 19 Apr 2012 Sanofi enters into a collaboration with the Michael J. Fox Foundation for a clinical trial in Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top